Trials / Recruiting
RecruitingNCT07288567
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (13 to 17 Years of Age)
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 166 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 13 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of KarXT for treatment of Schizophrenia in adolescents.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KarXT | Specified dose on specified days |
| OTHER | KarXT Matching Placebo | Specified dose on specified days |
Timeline
- Start date
- 2026-01-29
- Primary completion
- 2029-12-18
- Completion
- 2029-12-18
- First posted
- 2025-12-17
- Last updated
- 2026-04-07
Locations
44 sites across 5 countries: United States, Argentina, Colombia, Japan, Romania
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07288567. Inclusion in this directory is not an endorsement.